Table 1 Main characteristics of the studies included in the meta-analysis
Author | Year | Region | Study period | Study design | No. of patients | Age (years; median and range) | Male/female | Follow-up (months; median and range) | NOS or Jadad score | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sorafenib | Control | Sorafenib | Control | Sorafenib | Control | Sorafenib | Control | ||||||
Wang SN | 2014 | China | 2010.5–2012.11 | Prospective | 14 | 17 | 61.43 ± 10.15 | 59.71 ± 11.34 | 13/1 | 15/2 | 19 (14) | 19 (14) | 8 |
Zhang W | 2014 | China | 2009.8–2011.11 | Retrospective | 32 | 46 | 54.5 ± 1.6 | 51.7 ± 1.4 | 25/7 | 42/4 | – | – | 7 |
Bruix J | 2015 | 28 countries | 2008.8–2010.11 | RCT | 556 | 558 | 58 (24–85) | 60 (19–80) | 451/105 | 461/97 | 23·0 (12.7–36) | 22 (14.4–35.5) | 7 |
Antonious | 2016 | Caucasian | 2005.1–2013.1 | Retrospective | 16 | 14 | 62 (55–67.5) | 65.5 (53–71) | 13/3 | 10/4 | Median 38.2 | Median 38.2 | 7 |
Li J | 2016 | China | 2009.1–2013.12 | Retrospective | 12 | 24 | 49.8 ± 6 | 52.8 ± 6.9 | 12/0 | 24/0 | 23 (9–54) | 23 (9–54) | 7 |
Xia F | 2016 | China | 2010.9–2013.9 | Retrospective case control | 34 | 68 | 48 (21–78) | 57 (18–79) | 25/9 | 50/18 | Median 26 | Median 25 | 6 |
Chen BF | 2016 | China | 2009.6–2012.6 | Prospective | 24 | 46 | 48 ± 10 | 48 ± 11 | 22/2 | 40/6 | 36–60 | 36–60 | 7 |
Liao Y | 2017 | China | 2010.7–2013.7 | Retrospective | 14 | 28 | 47.4 ± 10.6 | 48.4 ± 11.0 | 11/3 | 26/2 | 13.6 (1.5–40.1) | 13.6 (1.5–40.1) | 8 |
Zhuang L | 2017 | China | 2010.1–2012.7 | Retrospective Case control | 27 | 54 | 48.2 ± 9.7 | 49.4 ± 9.4 | 25/2 | 50/4 | 14.5 (2.6–44.7) | 14.5 (2.6–44.7) | 8 |
Huang Y | 2019 | China | 2009.1–2016.12 | Retrospective | 16 | 33 | 52.25 ± 11.94 | 51.25 ± 11.87 | 12/4 | 30/3 | – | – | 8 |
Wang DS | 2019 | China | 2012.1–2013.11 | Retrospective | 98 | 111 | 46.5 (15–77) | 55 (30–79) | 86/12 | 100/11 | Median 14 | Median 15.4 | 8 |
Zhang XP | 2019 | China | 2009–2016 | Retrospective | 113 | 113 | 49 (43–56) | 48.0 (40–57) | 97/16 | 98/15 | – | – | 8 |
Sheng PC | 2020 | China | 2015.5–2018.1 | Retrospective | 49 | 36 | – | – | 36/13 | 28/8 | 35.4 (2–40.8) | 35.4 (2–40.8) | 8 |